Ads
related to: gilead hiv drugs- What's In BIKTARVY®?
Learn What's Inside BIKTARVY®
& Find Out How It Works
- Paying For BIKTARVY®
Financial And Insurance Support
For Eligible Patients - Learn More
- Treatment Information
Learn More About BIKTARVY®
At The Official Patient Website
- Patient Support Program
Financial And Insurance Support
For Eligible Patients - Learn More
- Learn About BIKTARVY®
Discover Info About BIKTARVY®
At The Official Patient Site
- Watch Our Commercial
Watch the BIKTARVY® Commercial
& Learn About Treatment
- What's In BIKTARVY®?
Search results
Gilead Sciences prevails in US government lawsuit over HIV drug patents
Reuters via Yahoo News· 1 year ago(Reuters) -A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents...
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
Zacks via Yahoo Finance· 2 years agoGilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the...
FDA Approves Gilead's New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients
Benzinga via Yahoo Finance· 1 year agoThe FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Sunlenca (lenacapavir), in combination...
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits
Benzinga via Yahoo Finance· 1 year agoGilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S....
U.S. FDA approves Gilead's long-acting HIV drug Sunlenca
Reuters via AOL· 1 year agoTreatment of HIV infections typically involves giving a combination of anti-retroviral HIV medicines...
Gilead profit tops expectations despite lower COVID drug sales, outlook raised
Reuters via Yahoo Finance· 2 years agoGilead Sciences Inc on Thursday posted a higher-than-expected third-quarter profit on the back of...
Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again
Investor's Business Daily· 3 weeks agoGilead stock pared its gains Friday after Gilead Sciences beat first-quarter sales forecasts on the...
Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot
Investor's Business Daily· 1 year agoGilead Sciences won Food and Drug Administration approval for a twice-a-year HIV treatment on...
Gilead Breaks Out In Bullish Volume As Its Cancer Drug Sales Nearly Double
Investor's Business Daily· 2 years agoGilead Sciences crushed third-quarter expectations as sales of its cancer drugs nearly doubled,...
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
Benzinga via Yahoo Finance· 2 years agoThe FDA has lifted the clinical hold placed on Gilead Sciences Inc's (NASDAQ: GILD) Investigational...
Ad
related to: gilead hiv drugs